Access to quality cancer treatment is essential for improving patient outcomes. Yet, many barriers still hinder access to clinical trials, especially in rural areas. It has been found that around 17% to 20% of Americans live in such areas, yet only 3% of oncologists practice there. This disparity significantly reduces the availability of care for cancer patients.
Challenges in Accessing Clinical Trials
A recent study revealed that more than 40% of Americans are unaware that clinical trials are an option for treatment. “A clinical trial should be the first option for a patient fighting cancer,” emphasized Dr. Hammonds. Historically, patients needed to travel to major medical centers to participate in these critical studies. However, community-based clinical trials are now becoming more prevalent.
The US Oncology Network is actively improving patient access to innovative treatments through its partnership with the Sarah Cannon Research Institute (SCRI). This collaboration focuses on conducting community-based clinical trials, effectively bridging the gap for patients in need.
Leveraging Data for Better Outcomes
Utilizing real-world data and evidence ensures that research represents a wider range of patients, particularly those from underrepresented communities. This strategy benefits regulatory bodies by enhancing their understanding of treatment outcomes across diverse populations.
Integrating Technology into Cancer Care
The convergence of healthcare and technology is transforming cancer treatment. Advanced information systems and artificial intelligence (AI) are helping integrate clinical trials into community practices more efficiently. “In the early 2000s, fewer than 10 oncological drugs received approval each year,” recalled Dr. Shumway. “In contrast, we expect close to 50 approvals this year.” The challenge lies in disseminating this rapid influx of information to healthcare providers.
- Ontada, a McKesson initiative, provides real-world oncology data to approximately 3,300 providers.
- Updates on National Comprehensive Cancer Network Guidelines are integrated within 24 hours.
- iKnowMed electronic health record incorporates biomarker testing to expedite diagnosis and treatment.
- Genospace platform matches eligible patients with clinical trial options, enhancing local access to advanced therapies.
Comprehensive Cancer Care
Patients diagnosed with cancer benefit from a multidisciplinary approach to care. This includes support from nurses, social workers, pharmacists, and psychologists. “More than half of cancer patients are treated in community settings,” noted Dr. Hammonds. By partnering with healthcare professionals, biopharmaceutical companies, and the broader oncology ecosystem, McKesson enhances treatment accessibility.
By addressing both clinical and emotional needs, collaboration with local organizations and advocacy groups fosters trust in the research process. These partnerships ensure patients receive needed support throughout their healing journey.
Looking Towards the Future
McKesson empowers community-based oncology practices by providing technology, clinical trial resources, and essential education. The goal is straightforward: deliver cutting-edge cancer care close to where patients live. Through innovation, collaboration, and a focus on enhancing access, McKesson is determined to bring hope home to cancer patients.
